Gene: B3GAT1

27087
CD57|GLCATP|GLCUATP|HNK1|LEU7|NK-1|NK1
beta-1,3-glucuronyltransferase 1
protein-coding
11q25
Ensembl:ENSG00000109956 MIM:151290 Vega:OTTHUMG00000167180 UniprotKB:Q9P2W7
NC_000011.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.286e-1 (AD)  2.210e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7928758chr11:134396073 (GRCh38.p7)T>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SBF10.926
ZC3H7B0.919
HDAC50.918
RAB11FIP30.918
EVI5L0.912
SENP30.912
PPP1R9B0.911
PPP2R2C0.909
MAPK8IP10.909
BAP10.906

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.718
OR4F29-0.697
IL18RAP-0.438
TFPI2-0.425
KCNJ15-0.418
IL24-0.409
SLAMF6-0.408
CST7-0.408
LILRB2-0.401
CD48-0.398

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB01694D-tartaric acidSmall Molecule147-71-7ExperimentalTarget
DB03435Uridine-5'-DiphosphateSmall Molecule58-98-0ExperimentalTarget
DB09459Tartaric acidSmall MoleculeApprovedEnzyme
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of B3GAT1 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GAT1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GAT1 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of B3GAT1 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of B3GAT1 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of B3GAT1 mRNA19770486
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of B3GAT1 mRNA28522335
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to B3GAT1 promoter]19654925
C006780bisphenol Abisphenol A results in decreased expression of B3GAT1 mRNA25181051
C025191bromodichloromethane[bromodichloromethane co-treated with Dietary Fats] results in increased expression of B3GAT1 protein24211274
D019256Cadmium ChlorideCadmium Chloride results in decreased methylation of B3GAT1 promoter22457795
D003300CopperCopper deficiency results in increased expression of B3GAT1 mRNA26033743
C014347decitabinedecitabine affects the expression of B3GAT1 mRNA23300844
D002945CisplatinCisplatin affects the expression of B3GAT1 mRNA23300844
D004041Dietary Fats[bromodichloromethane co-treated with Dietary Fats] results in increased expression of B3GAT1 protein24211274
D004041Dietary FatsDietary Fats results in decreased expression of B3GAT1 mRNA28031460
D019422Dietary SucroseDietary Sucrose results in increased expression of B3GAT1 mRNA26033743
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of B3GAT1 mRNA17942915
D004052DiethylnitrosamineMET protein inhibits the reaction [Diethylnitrosamine results in increased expression of B3GAT1 mRNA]17942915
D000431EthanolEthanol results in decreased expression of B3GAT1 protein28919490
C069837fullerene C60fullerene C60 results in decreased expression of B3GAT1 mRNA19167457
D005839GentamicinsGentamicins results in decreased expression of B3GAT1 mRNA22061828
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of B3GAT1 protein26067464
D008627Mercuric ChlorideMercuric Chloride results in decreased expression of B3GAT1 mRNA16507785
C028007nickel monoxidenickel monoxide results in decreased expression of B3GAT1 mRNA19167457
C029938nickel sulfatenickel sulfate results in decreased expression of B3GAT1 mRNA16780908
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GAT1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of B3GAT1 mRNA26272509
D014212TretinoinTretinoin results in decreased expression of B3GAT1 mRNA21934132
C012589trichostatin Atrichostatin A results in decreased expression of B3GAT1 mRNA24935251
D014635Valproic AcidValproic Acid results in increased methylation of B3GAT1 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of B3GAT1 gene25560391
C025643vinclozolinvinclozolin affects the expression of B3GAT1 mRNA19015723
D015032ZincZinc deficiency results in increased expression of B3GAT1 mRNA18356318
D015032ZincZinc deficiency results in decreased expression of B3GAT1 protein18224284

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008499UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity-IEA-  
GO:0015018galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity-IBA21873635  
GO:0015018galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity-ISS-  
GO:0015018galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity-TAS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005975carbohydrate metabolic process-IBA21873635  
GO:0005975carbohydrate metabolic process-TAS10783264  
GO:0006486protein glycosylation-IEA-  
GO:0030203glycosaminoglycan metabolic process-TAS-  
GO:0050650chondroitin sulfate proteoglycan biosynthetic process-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IBA21873635  
GO:0000139Golgi membrane-ISS-  
GO:0000139Golgi membrane-TAS-  
GO:0005576extracellular region-IEA-  
GO:0005789endoplasmic reticulum membrane-ISS-  
GO:0016021integral component of membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
KEGG ID KEGG Term
hsa00532Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate
hsa00534Glycosaminoglycan biosynthesis - heparan sulfate / heparin
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1630316Glycosaminoglycan metabolismTAS
R-HSA-1638091Heparan sulfate/heparin (HS-GAG) metabolismTAS
R-HSA-1793185Chondroitin sulfate/dermatan sulfate metabolismTAS
R-HSA-1971475A tetrasaccharide linker sequence is required for GAG synthesisTAS
R-HSA-71387Metabolism of carbohydratesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal